Volume 2, Issue 11
Acknowledgementsp. 1145
Acknowledgements: Clinical Investigation (2012) Vol 2, Iss 11
Editorialp. 1053–105
Anti-MET Targeted therapy for NSCLC: has it come of age?
Author(s): Patrick C Ma
News and Viewsp. 1057–106
Results published on Phase II clinical trial for dengue vaccine
Research Updatep. 1061–106
The European network for Translational Research in Atrial Fibrillation
Author(s): Stephane Hatem, Ulrich Schotten, Stephan Rohr, Dobromir Dobrev, Ursula Ravens, Andreas Goette, Burkert Pieske, Jens Kockskamper, Uwe Lendeckel, Barbara Casadei,Paulus Kirchhof, Frank Ulrich Muller, Pierre Jais, Ali Oto,John A Camm
Commentaryp. 1069–107
Placebo mechanisms for drug dose reduction: what is the evidence?
Author(s): Paul Enck, Sibylle Klosterhalfen
Clinical Trail Methodologyp. 1073–108
Considerations in the design of clinical trials for relapsing multiple sclerosis
Author(s): Richard Nicholas, Tim Friede
Review: Clinical Trail Outcomesp. 1085–110
Novel treatments of interstitial cystitis/bladder pain syndrome based on pathophysiology
Author(s): Hann-Chorng Kuo
Review Articlep. 1101–110
An update of adjuvant treatments for localized advanced gastric cancer
Author(s): Yoon-Koo Kang
Review: Clinical Trail Outcomesp. 1109–112
Recent advances in treatment of metastatic colorectal cancer
Author(s): Sigurdis Haraldsdottir & Richard M Goldberg
Review: Clinical Trail Outcomesp. 1123–113
Everolimus for the treatment of advanced pancreatic neuroendocrine tumors
Author(s): Paola Tomassetti, Monica Cevenini, Elena Guidetti, Giulia Cacciari, Maria Luigia Cipollini, Elena Galassi, Maria Camilla Fabbri, Francesca Nori, Davide Campana, Roberto Corinaldesi ,Roberto De Giorgio
Review: Clinical Trail Outcomesp. 1133–114
Rilpivirine in the treatment of HIV infection: evidence from the ECHO and THRIVE studies
Author(s): Pedro Cahn
